Prostate-specific antigen (PSA) isoform p2PSA in prostate cancer screening: Systematic review of current evidence and further perspectives

Rivista Italiana della Medicina di Laboratorio

Volumn 8, Issue 4, 2012, Pages 231-238

  Lippi, Giuseppe ^a   Aloe, Rosalia ^a   Mattiuzzi, Camilla ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Ospedale di Trento   (Italy)

Author keywords

p2PSA; Prostate cancer; Prostate health index; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HUMAN; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84876246907     PISSN: 1825859X     EISSN: 20396821     Source Type: Journal    
DOI: 10.1007/s13631-012-0067-7     Document Type: Review

References (44)

1. R. Siegel D. Naishadham A. Jemal 2012 Cancer statistics, 2012 CA Cancer J Clin 62 10 29 22237781 10.3322/caac.20138
2. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute. I numeri del cancro in Italia 2011. http://www.epicentro.iss.it/temi/ tumori/italiaEpid.asp. Accessed 27 October 2012
3. D.D. Brooks A. Wolf R.A. Smith, et al. 2010 Prostate cancer screening 2010: updated recommendations from the American Cancer Society J Natl Med Assoc 102 423 429 20533778
4. R. Chou J.M. Croswell T. Dana, et al. 2011 Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 155 762 771 21984740
5. A. Heidenreich J. Bellmunt M. Bolla, et al. 2011 EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 61 71 21056534 10.1016/j.eururo.2010.10.039
6. A. Sciarra S. Cattarino A. Gentilucci, et al. 2011 Update on screening in prostate cancer based on recent clinical trials Rev Recent Clin Trials 6 7 15 20868347 10.2174/157488711793980165
7. S. Carlsson A.J. Vickers M. Roobol, et al. 2012 Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review J Clin Oncol 30 2581 2584 22711853 10.1200/JCO.2011.40.4327
8. T.J. Wilt M.K. Brawer K.M. Jones, et al. 2012 Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 203 213 22808955 10.1056/NEJMoa1113162 1:CAS:528:DC%2BC38XhtFSgurvO
9. E.A. Heijnsdijk E.M. Wever A. Auvinen, et al. 2012 Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 595 605 22894572 10.1056/NEJMoa1201637 1:CAS:528:DC%2BC38Xht1Chu77I
10. K.L. Greene P.C. Albertsen R.J. Babaian, et al. 2009 Prostate specific antigen best practice statement: 2009 update J Urol 182 2232 2241 19781717 10.1016/j.juro.2009.07.093 1:CAS:528:DC%2BD1MXhtlyqu7bF
11. G. Lippi M. Montagnana G.C. Guidi M. Plebani 2009 Prostatespecific antigen-based screening for prostate cancer in the third millennium: useful or hype? Ann Med 41 480 489 19657768 10.1080/07853890903156468 1:CAS:528: DC%2BD1MXhsVCrsL7P
12. G. Lippi 2011 Re: Jean-Nicolas Cornu, Géraldine Cancel-Tassin, Valérie Ondet et al. Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis Eur Urol 59 197 201 10.1016/j.eururo.2010.10.006
13. M.Z. Zhang Y.P. Lu 2012 From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma Chin Med J (Engl) 125 1643 1649 1:CAS:528:DC%2BC38XpsFOnsrs%3D
14. P. Whiting A.W. Rutjes J.B. Reitsma, et al. 2003 The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 25 14606960 10.1186/1471-2288-3-25
15. J.P. Higgins S.G. Thompson J.J. Deeks D.G. Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 557 560 12958120 10.1136/bmj.327.7414.557
16. W.J. Catalona G. Bartsch H.G. Rittenhouse, et al. 2003 Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 6Pt1 2181 2185 14634374 10.1097/01.ju.0000095460.12999.43 1:CAS:528:DC%2BD3sXpvFSksL4%3D
17. S.D. Mikolajczyk W.J. Catalona C.L. Evans, et al. 2004 Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 1017 1025 15054080 10.1373/clinchem.2003.026823 1:CAS:528:DC%2BD2cXltFOjs7o%3D
18. W.J. Catalona G. Bartsch H.G. Rittenhouse, et al. 2004 Serum proprostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen J Urol 171 6Pt1 2239 2244 15126794 10.1097/01.ju.0000127737.94221.3e
19. L.J. Sokoll Y. Wang Z. Feng, et al. 2008 [-2]proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study J Urol 180 539 543 18550118 10.1016/j.juro.2008.04.015 1:CAS:528:DC%2BD1cXpsFyiu74%3D
20. C. Stephan A.M. Kahrs H. Cammann, et al. 2009 A [-2]proPSAbased artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases Prostate 69 198 207 18942119 10.1002/pros.20872 1:CAS:528:DC%2BD1MXivVGhsbs%3D
21. F.H. Jansen R.H. van Schaik J. Kurstjens, et al. 2010 Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 921 927 20189711 10.1016/j.eururo.2010.02.003 1:CAS:528:DC%2BC3cXnvFGrsb8%3D
22. L.J. Sokoll M.G. Sanda Z. Feng, et al. 2010 A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 1193 1200 20447916 10.1158/1055-9965.EPI-10- 0007
23. B.V. Le C.R. Griffin S. Loeb, et al. 2010 [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 1355 1359 20171670 10.1016/j.juro.2009.12.056 1:CAS:528:DC%2BC3cXkvFOnurw%3D
24. G. Guazzoni L. Nava M. Lazzeri, et al. 2011 Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 214 222 21482022 10.1016/j.eururo.2011.03.052 1:CAS:528:DC%2BC3MXot1agu7s%3D
25. W.J. Catalona A.W. Partin M.G. Sanda, et al. 2011 A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 1650 1655 21419439 10.1016/j.juro.2010.12.032 1:CAS:528:DC%2BC3MXksFSqs7c%3D
26. Perdonà S, Bruzzese D, Ferro M et al (2012) Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. doi: 10.1002/pros.22561. [Epub ahead of print]
27. E. Stenner W. Micheli A. Bussani, et al. 2008 Comparison of Hybritech and WHO standardization applied to access Hybritech total PSA assay on UniCel® RIMeL/IJLaM 4 43 46 1:CAS:528:DC%2BD1cXmt1Wnsr8%3D
28. F.H. Schröder J. Hugosson M.J. Roobol, et al. 2012 ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 981 990 22417251 10.1056/NEJMoa1113135
29. Y. Naya H.A. Fritsche V.A. Bhadkamkar, et al. 2005 Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer Urol Oncol 23 16 21 15885578 10.1016/j.urolonc.2004.07.017 1:CAS:528:DC%2BD2MXktVKgt7g%3D
30. Y. Liang D.P. Ankerst N.S. Ketchum, et al. 2001 Prospective evaluation of operating characteristics of prostate cancer detection biomarkers J Urol 185 104 110 10.1016/j.juro.2010.08.088
31. S. Isharwal D.V. Makarov L.J. Sokoll, et al. 2011 ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program Urology 77 763.e1 e6 10.1016/j.urology.2010.07.526
32. J.S. Blanchet A. Houlgatte X. Durand, et al. 2010 The [-2]proPSA and the Prostate Health Index (phi) improve the detection of prostate cancer for patients with total PSA between 1.8 and 8.0 ng/mL J Mens Health 7 345 10.1016/j.jomh.2010.09.206
33. J.S. Blanchet X. Durand A. Houlgatte, et al. 2010 The Beckman Coulter prostate health index (phi) increases the specificity of detection of prostate cancer and reduces the number of negative biopsies J Mens Health 7 346
34. J.S. Blanchet S. Vincendeau X. Durand, et al. 2010 Detection of aggressive prostate cancer using [-2]proPSA and the prostate health index J Mens Health 7 346
35. S. Vincendeau J. Ramirez X. Durand, et al. 2010 The Beckman Coulter prostate health index (phi) improves diagnostic accuracy in prostate cancer detection Eur Urol Suppl 9 309 10.1016/S1569-9056(10)60965-7
36. A. Houlgatte S. Vincendeau F. Desfemmes, et al. 2012 Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients Prog Urol 22 279 283 22515924 10.1016/j.purol.2011.09.009 1:STN:280:DC%2BC38rmtlaqug%3D%3D
37. M. Ferro D. Bruzzese S. Perdonà, et al. 2012 Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers Clin Chim Acta 413 1274 1278 22542564 10.1016/j.cca.2012.04.017 1:CAS:528:DC%2BC38Xmslyhu7g%3D
38. M.B. Nichol J. Wu J. Huang, et al. 2012 Cost-effectiveness of Prostate Health Index for prostate cancer detection BJU Int 110 353 362 22077934 10.1111/j.1464-410X.2011.10751.x
39. M.B. Nichol J. Wu J.J. An, et al. 2011 Budget impact analysis of a new prostate cancer risk index for prostate cancer detection Prostate Cancer Prostatic Dis 14 253 261 21537346 10.1038/pcan.2011.16 1:STN:280: DC%2BC3MjmtlyksA%3D%3D
40. F. Ceriotti M. Postillo L. Fasoli F. Dorigatti 2011 Pre-analytical phase of [-2]proPSA measurement and Prostate Health Index calculation Biochim Clin 35 373 376
41. A. Semjonow T. Köke E. Eltze, et al. 2010 Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 43 926 928 20450900 10.1016/j.clinbiochem.2010.04.062 1:CAS:528:DC%2BC3cXnsVaqtbo%3D
42. S. Tadtayev T.A. McNicholas G.B. Boustead 2012 Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 455 66 10.1016/j.eururo.2011.10.038
43. G. Lippi R. Aloe G. Cervellin 2011 p2PSA but not total and free PSA increases after myocardial infarction: results of a preliminary investigation Int J Cardiol 153 119 21968074 10.1016/j.ijcard.2011.09.044
44. L.J. Sokoll D.W. Chan G.G. Klee, et al. 2012 Multi-center analytical performance evaluation of the Access Hybritech immunoassay Clin Chim Acta 413 1279 1283 22542565 10.1016/j.cca.2012.04.015 1:CAS:528:DC%2BC38XmvFKiu7g%3D